Skip to main content
Erschienen in: International Ophthalmology 6/2023

18.01.2023 | Original Paper

Visual evoked potential changes following Botox administration in patients with blepharospasm

verfasst von: Mehmet Tahir Eski, Kuddusi Teberik, Taha Sezer, Aziz Hudai Ayasli, Ayhan Ozturk

Erschienen in: International Ophthalmology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To examine visual evoked potential (VEP) changes following botulinum toxin type A (BTA) administration in patients with blepharospasm.

Methods

Patients diagnosed with blepharospasm receiving BTA administration were included in the study. Three groups, a control group and two study groups (patients examined 14 days after BTA administration—Study Group 1, and patients examined 28 days after BTA administration—Study Group 2) were evaluated. Dilated fundus examinations were performed following detailed ophthalmological examinations and VEP tests. Keypoint (Dantec, Denmark) and ISCEV criteria were adopted for pattern VEP (PVEP) recording. BTA was applied in the form of local injections at a total 15–30 units, at 2.5–5 units per injection.

Results

A mean 19.4 ± 3.2 units of BTA was used for each eye. N70 (ms), P100 (ms), and P100 (uV) values were statistically significantly lower in both study groups following drug administrations compared to the control group (p < 0.001 for all). Significant positive correlation was observed between increased P100 amplitudes and age in the control group (p = 0.008, r = 0.200). Significant negative correlation was observed between the BTA units used and decreased P100 amplitudes in both study groups 1 and 2 following drug administrations (p = 0.017, r = − 0.180 and p = 0.043, r = − 0.153, respectively).

Conclusion

VEP may be an important method in the diagnosis and follow-up of blepharospasm and in determining the success of drug administration and additional therapeutic requirements.
Literatur
1.
Zurück zum Zitat Barbosa ER, Silva HC, Haddad MS et al (1996) Blepharospasm: treatment with botulinum toxin. Rev Hosp Clin Fac Med Sao Paulo 51:220–223PubMed Barbosa ER, Silva HC, Haddad MS et al (1996) Blepharospasm: treatment with botulinum toxin. Rev Hosp Clin Fac Med Sao Paulo 51:220–223PubMed
2.
Zurück zum Zitat Papapetropoulos S, Singer C (2007) Botulinum toxin in movement disorders. Semin Neurol 27:183–194CrossRefPubMed Papapetropoulos S, Singer C (2007) Botulinum toxin in movement disorders. Semin Neurol 27:183–194CrossRefPubMed
3.
4.
Zurück zum Zitat Cossu G, Mereu A, Deriu M et al (2006) Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey. Mov Disord 21:2005–2008CrossRefPubMed Cossu G, Mereu A, Deriu M et al (2006) Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey. Mov Disord 21:2005–2008CrossRefPubMed
5.
Zurück zum Zitat Nutt JG, Muenter MD, Aronson A et al (1988) Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3:188–194CrossRefPubMed Nutt JG, Muenter MD, Aronson A et al (1988) Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3:188–194CrossRefPubMed
7.
Zurück zum Zitat Fantato A, Parulekar M, Elston J (2019) A trial of a mechanical device for the treatment of blepharospasm. Eye (Lond) 33:1803–1808CrossRefPubMed Fantato A, Parulekar M, Elston J (2019) A trial of a mechanical device for the treatment of blepharospasm. Eye (Lond) 33:1803–1808CrossRefPubMed
8.
Zurück zum Zitat Berardelli A, Curra A (2002) Pathophysiology and treatment of cranial dystonia. Mov Disord 17(Suppl 2):S70-74CrossRefPubMed Berardelli A, Curra A (2002) Pathophysiology and treatment of cranial dystonia. Mov Disord 17(Suppl 2):S70-74CrossRefPubMed
9.
Zurück zum Zitat Mukai Y, Kaji R (2011) Use of botulinum neurotoxin therapy. Brain Nerve 63:775–784PubMed Mukai Y, Kaji R (2011) Use of botulinum neurotoxin therapy. Brain Nerve 63:775–784PubMed
10.
11.
Zurück zum Zitat Jankovic J (1998) Medical therapy and botulinum toxin in dystonia. Adv Neurol 78:169–183PubMed Jankovic J (1998) Medical therapy and botulinum toxin in dystonia. Adv Neurol 78:169–183PubMed
12.
Zurück zum Zitat Hassell TJW, Charles D (2020) Treatment of blepharospasm and oromandibular dystonia with botulinum toxins. Toxins (Basel) 12:E269CrossRef Hassell TJW, Charles D (2020) Treatment of blepharospasm and oromandibular dystonia with botulinum toxins. Toxins (Basel) 12:E269CrossRef
13.
Zurück zum Zitat Berardelli A, Conte A (2021) The use of botulinum toxin for treatment of the dystonias. Handb Exp Pharmacol 263:107–126CrossRefPubMed Berardelli A, Conte A (2021) The use of botulinum toxin for treatment of the dystonias. Handb Exp Pharmacol 263:107–126CrossRefPubMed
14.
Zurück zum Zitat Tamcelik N (2011) Ocular electrophysiology, 2011th edn. Turkish Ophthalmological Association Education Publications, Istanbul Tamcelik N (2011) Ocular electrophysiology, 2011th edn. Turkish Ophthalmological Association Education Publications, Istanbul
15.
Zurück zum Zitat Jankovic J, Kenney C, Grafe S et al (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 24:407–413CrossRefPubMed Jankovic J, Kenney C, Grafe S et al (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 24:407–413CrossRefPubMed
16.
Zurück zum Zitat Namiguchi K, Mizoue S, Ohta K et al (2018) Effect of botulinum Toxin A treatment on eyelid pressure in eyes with blepharospasm. Curr Eye Res 43:896–901CrossRefPubMed Namiguchi K, Mizoue S, Ohta K et al (2018) Effect of botulinum Toxin A treatment on eyelid pressure in eyes with blepharospasm. Curr Eye Res 43:896–901CrossRefPubMed
17.
Zurück zum Zitat Brigell M, Bach M, Barber C et al (1998) Guidelines for calibration of stimulus and recording parameters used in clinical electrophysiology of vision. Calibration Standard Committee of the International Society for Clinical Electrophysiology of Vision (ISCEV). Doc Ophthalmol 95:1–14CrossRefPubMed Brigell M, Bach M, Barber C et al (1998) Guidelines for calibration of stimulus and recording parameters used in clinical electrophysiology of vision. Calibration Standard Committee of the International Society for Clinical Electrophysiology of Vision (ISCEV). Doc Ophthalmol 95:1–14CrossRefPubMed
19.
Zurück zum Zitat Patel B, Weinstein G (1998) Diagnosis and treatment of blepharspazm. Mosby Press, Louis St. In Nesi FA, Lisman RD, Levien MR Patel B, Weinstein G (1998) Diagnosis and treatment of blepharspazm. Mosby Press, Louis St. In Nesi FA, Lisman RD, Levien MR
20.
Zurück zum Zitat Powers JM (1982) Decongestant-induced blepharospasm and orofacial dystonia. JAMA 247:3244–3245CrossRefPubMed Powers JM (1982) Decongestant-induced blepharospasm and orofacial dystonia. JAMA 247:3244–3245CrossRefPubMed
21.
Zurück zum Zitat Jankovic J, Orman J (1984) Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 16:371–376PubMed Jankovic J, Orman J (1984) Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 16:371–376PubMed
23.
Zurück zum Zitat Nicoletti AGB, Aoki L, Nahas TR et al (2010) Essential blepharospasm: literature review. Arq Bras Oftalmol 73:469–473CrossRefPubMed Nicoletti AGB, Aoki L, Nahas TR et al (2010) Essential blepharospasm: literature review. Arq Bras Oftalmol 73:469–473CrossRefPubMed
24.
Zurück zum Zitat Odom JV, Bach M, Barber C et al (2004) Visual evoked potentials standard (2004). Doc Ophthalmol 108:115–123CrossRefPubMed Odom JV, Bach M, Barber C et al (2004) Visual evoked potentials standard (2004). Doc Ophthalmol 108:115–123CrossRefPubMed
25.
Zurück zum Zitat Finsterer J, Stöllberger C, Shinar Y (2002) Cranial nerve lesions and abnormal visually evoked potentials associated with the M694V mutation in familial Mediterranean fever. Clin Rheumatol 21:317–321CrossRefPubMed Finsterer J, Stöllberger C, Shinar Y (2002) Cranial nerve lesions and abnormal visually evoked potentials associated with the M694V mutation in familial Mediterranean fever. Clin Rheumatol 21:317–321CrossRefPubMed
26.
Zurück zum Zitat Odom JV, Bach M, Brigell M et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133:1–9CrossRefPubMed Odom JV, Bach M, Brigell M et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133:1–9CrossRefPubMed
27.
Zurück zum Zitat Kurysheva NI, Maslova EV, Trubilina AV et al (2018) Pattern visual evoked potentials and their relation to the peripapillary and retrobulbar blood flow in glaucoma. Vestn Oftalmol 134:19–27CrossRefPubMed Kurysheva NI, Maslova EV, Trubilina AV et al (2018) Pattern visual evoked potentials and their relation to the peripapillary and retrobulbar blood flow in glaucoma. Vestn Oftalmol 134:19–27CrossRefPubMed
28.
Zurück zum Zitat Amini Vishteh R, Mirzajani A, Jafarzadehpur E et al (2020) Evaluation of visual evoked potential binocular summation after corneal refractive surgery. Doc Ophthalmol 140:181–188CrossRefPubMed Amini Vishteh R, Mirzajani A, Jafarzadehpur E et al (2020) Evaluation of visual evoked potential binocular summation after corneal refractive surgery. Doc Ophthalmol 140:181–188CrossRefPubMed
29.
Zurück zum Zitat Lavinsky J, Gus PI, Ehlers JA et al (2000) Visual-evoked potentials: assessment of retrobulbar and peribulbar anesthesia. J Cataract Refract Surg 26:1529–1532CrossRefPubMed Lavinsky J, Gus PI, Ehlers JA et al (2000) Visual-evoked potentials: assessment of retrobulbar and peribulbar anesthesia. J Cataract Refract Surg 26:1529–1532CrossRefPubMed
30.
Zurück zum Zitat Alimgil ML, Benian Ö, Esgin H (2001) Tiroid Orbitopatide Oküler Nabız Genliği. Görme Alanı ve Vep MNO 8:414–416 Alimgil ML, Benian Ö, Esgin H (2001) Tiroid Orbitopatide Oküler Nabız Genliği. Görme Alanı ve Vep MNO 8:414–416
31.
Zurück zum Zitat Clauser LC, Tieghi R, Galie’ M et al (2012) Surgical decompression in endocrine orbitopathy. Visual evoked potential evaluation and effect on the optic nerve. J Craniomaxillofac Surg 40:621–625CrossRefPubMed Clauser LC, Tieghi R, Galie’ M et al (2012) Surgical decompression in endocrine orbitopathy. Visual evoked potential evaluation and effect on the optic nerve. J Craniomaxillofac Surg 40:621–625CrossRefPubMed
32.
33.
Zurück zum Zitat Suzuki Y, Kiyosawa M, Wakakura M et al (2019) Glucose hypometabolism in the visual cortex proportional to disease severity in patients with essential blepharospasm. Neuroimage Clin 24:101995CrossRefPubMedPubMedCentral Suzuki Y, Kiyosawa M, Wakakura M et al (2019) Glucose hypometabolism in the visual cortex proportional to disease severity in patients with essential blepharospasm. Neuroimage Clin 24:101995CrossRefPubMedPubMedCentral
Metadaten
Titel
Visual evoked potential changes following Botox administration in patients with blepharospasm
verfasst von
Mehmet Tahir Eski
Kuddusi Teberik
Taha Sezer
Aziz Hudai Ayasli
Ayhan Ozturk
Publikationsdatum
18.01.2023
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 6/2023
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-023-02639-9

Weitere Artikel der Ausgabe 6/2023

International Ophthalmology 6/2023 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.